{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:13:00Z","timestamp":1788592380955,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.numecd.2026.104777","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:09:14Z","timestamp":1777590554000},"page":"104777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bempedoic acid for prevention of atherosclerotic cardiovascular disease: from trials to clinical practice"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-2234","authenticated-orcid":false,"given":"Furio","family":"Colivicchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8586-9930","authenticated-orcid":false,"given":"Stefania Angela","family":"Di Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scicchitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico Luigi","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.numecd.2026.104777_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40292-025-00708-x","article-title":"Reducing LDL-cholesterol to very low levels: sailing between established benefits and potential risks","volume":"32","author":"Di Fusco","year":"2025","journal-title":"High Blood Pres Cardiovasc Prev"},{"key":"10.1016\/j.numecd.2026.104777_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133290","article-title":"On the behalf of BRING-UP prevention. LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry","volume":"433","author":"Colivicchi","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2026.104777_bib3","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"10.1016\/j.numecd.2026.104777_bib4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.numecd.2026.104777_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003121","article-title":"Lipid, blood pressure meta-analysis collaboration G, the international lipid expert P. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis","volume":"17","author":"Cicero","year":"2020","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.numecd.2026.104777_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2459\/JCM.0000000000001108","article-title":"Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper","volume":"22","author":"Colivicchi","year":"2021","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.numecd.2026.104777_bib7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"42","key":"10.1016\/j.numecd.2026.104777_bib8","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.numecd.2026.104777_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.numecd.2026.104777_bib10","first-page":"747","volume":"26","author":"Colivicchi","year":"2025","journal-title":"G Ital Cardiol"},{"issue":"9976","key":"10.1016\/j.numecd.2026.104777_bib11","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"issue":"10349","key":"10.1016\/j.numecd.2026.104777_bib12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104777_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical tials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.numecd.2026.104777_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.numecd.2026.104777_bib15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ehjcvp\/pvab064","article-title":"Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model","volume":"8","author":"Jadhav","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.numecd.2026.104777_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2026.104777_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2026.104777_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf777","article-title":"Oral triple combination lipid-lowering therapy and LDL cholesterol goal attainment: a simulation using the SANTORINI study cohort","author":"Katzmann","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.numecd.2026.104777_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","article-title":"Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: a randomized, controlled trial","volume":"15","author":"Rubino","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2026.104777_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104777_bib21","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104777_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2026.120636","article-title":"Seventeen years to change practice: will the 2025 ESC\/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?","volume":"413","author":"Ray","year":"2026","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.numecd.2026.104777_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/CIRCULATIONAHA.125.075388","article-title":"Triple versus dual lipid-lowering therapy in acute coronary syndrome: the ES-BempedACS randomized clinical trial","volume":"153","author":"Raposeiras-Roub\u00edn","year":"2026","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.numecd.2026.104777_bib24","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.numecd.2026.104777_bib25","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104777_bib26","article-title":"Cost-effectiveness of bempedoic acid in high cardiovascular risk patients with statin intolerance: an analysis of the CLEAR outcomes trial","author":"Nicholls","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.numecd.2026.104777_bib27","doi-asserted-by":"crossref","unstructured":"Blaum C, Brunner FJ, Go\u00dfling A, Kr\u00f6ger F, Bay B, Lorenz T, et al. Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort. Clin Ther. 202;43(9):1583-1600. doi: 10.1016\/j.clinthera.2021.07.019.","DOI":"10.1016\/j.clinthera.2021.07.019"},{"issue":"13","key":"10.1016\/j.numecd.2026.104777_bib28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/eurjpc\/zwaf114","article-title":"Rethinking cardiovascular prevention: cost-effective cholesterol lowering for statin-intolerant patients in Australia and the UK","volume":"32","author":"Morton","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2026.104777_bib29","series-title":"Final appraisal document \u2013 bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia","year":"2021"},{"issue":"5","key":"10.1016\/j.numecd.2026.104777_bib30","first-page":"318","article-title":"STEP-RCV Project: ScienTific Expert Panel per i pazienti a rischio cardiovascolare alto e molto alto: come ottimizzare la terapia","volume":"25","author":"Colivicchi","year":"2024","journal-title":"G Ital Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104777_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11883-026-01400-8","article-title":"Upfront combination or stepwise escalation: personalising LDL-C reduction in clinical practice","volume":"28","author":"Pirillo","year":"2026","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.numecd.2026.104777_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2026.120636","article-title":"Seventeen years to change practice: will the 2025 ESC\/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?","volume":"413","author":"Ray","year":"2026","journal-title":"Atherosclerosis"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326002395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326002395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:02:33Z","timestamp":1788591753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326002395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0939475326002395"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104777","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bempedoic acid for prevention of atherosclerotic cardiovascular disease: from trials to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104777"}}